The US marijuana space attracted over US$10 billion in investment this year, says an industry economist and researcher.
According to a new report from NBC News, Beau Whitney, vice president and senior economist with cannabis research and data venture New Frontier Data, has confirmed that investors added US$10 billion throughout 2018 to the American cannabis market.
The researcher expects 2019 to reach over US$16 billion for the total North American cannabis scene.
“Investors are getting much savvier when it comes to this space because even just a couple of years ago, you’d throw money at it and hope that something would stick,” Whitney said. “But now investors are much more discerning.”
The ability of investors in the space to pick out established business models in the emerging market has grown as the industry continues to mature.
“It’s abundantly clear that the investor appetite has moved from people with cultivation licenses and ambitious programs to build greenhouse capacity … to companies that are investing in portfolios of intellectual property,” Richard Carleton, CEO of the Canadian Securities Exchange, said during a panel at the Arcview Investor Forum in Las Vegas.
Carleton’s comment alludes to the increased scrutiny the space is receiving from investors. Market watchers are increasingly aware that the idea of a successful cannabis business doesn’t necessarily mean only growing the plant anymore.
The Canadian exchange saw its listings and investments grow as it opened its doors to US-based cannabis businesses seeking a public listing.
In October, Carleton said the CSE had seen C$1.5 billion raised for its US cannabis listings throughout the year. He added that the figure is in constant flux as new issuers appear regularly on the exchange.
Whitney said the investment figure seen in 2018 for the US cannabis market topped the amount for the past three years, representing rapidly growing interest in the space.
As more US states seek to add revenues from cannabis programs, the overall industry is set to continue growing in 2019. Click here to read more about next year’s cannabis outlook.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.